Contract development and manufacturing organization Ajinomoto Bio-Pharma Services is buying out partner Granules India to take full control of their Indian active pharmaceutical ingredient manufacturing joint venture. The acquisition is part of Ajinomoto Bio-Pharma’s strategy to offer a “more seamless” support supply-chain to its biopharmaceutical corporate customers, reflecting what is become a growing CDMO industry trend.
Ajinomoto Bio-Pharma – a wholly owned subsidiary of Tokyo-based Ajinomoto – and Granules India currently each own 50% of the...
